Humana surges post-market on boost in 2027 Medicare Advantage Star Ratings
Humana surged in after-hours trading on expectations of a higher Medicare Advantage star rating in 2027.
The current price of 387.12 is located above the 20-day low support level of 369.13, suggesting the possibility of a rebound, and remains below the resistance level of 415.77, leaving room for upside. Therefore, consider buying near the support level.
If the price reaches the resistance level of 415.77, take profit; if the price falls to the support level of 369.13, cut losses. This is a first-person simulation based on the resistance and support levels suggested by REPORTING.
RSI(14) 56.5 – Neutral, neither overbought nor oversold; moving averages in a bullish alignment – supporting the upward trend; volume 1.59x the 20-day average – active trading; 7-day volatility/return +1.8% – gentle upward momentum.
In the past, Humana has shown similar price increase patterns in response to positive news, rising by +1.6% on 2026-09-25, +2.1% on 2026-09-04, +2.2% on 2026-09-02, +3.1% on 2026-08-20, and +0.9% on 2026-08-10, which suggests a tendency for the stock price to rise steadily following favorable announcements.
The actual return of 11.5% significantly exceeded the target of a 4.5% projected return. Technical indicators and past upward patterns sufficiently suggested the potential for an increase, resulting in gains that surpassed the target price of 415.77. However, the fact that the prediction was conservative needs to be reflected in future target settings.
For the next trade, when setting the target price, consider a more aggressive upward potential to revise the target upward, while flexibly managing the stop-loss line in the event of increased volatility. In addition, when similar themes and favorable news arise, optimize the entry timing by checking for a surge in trading volume and a neutral RSI range.